Dr. Khawlah Dhamen. Assistant Professor Faculity of Medicine
|
|
- Alaina Parks
- 5 years ago
- Views:
Transcription
1 Dr. Khawlah Dhamen Assistant Professor Faculity of Medicine
2 1. Starts with prediction=an idea & hypothesis What helps? Awareness of the beneficial effects of plants and animal products (natural sources) Chemical identification of a wide variety of natural mediators and the possibility of modifying them chemically
3 e.g. epinephrine, norepinehrine acetylcholine histamine prostaglandins endogenous opioids hormones etc Avoid chemicals with highly reactive groups (toxic)
4 2. Design and synthesis of useful drugs or substances through simple techniques or with the help of advanced technology. Plant fractionation, chromatographic experiments identification of the active ingredients isolation purification good drug (recently most drugs of plant source could be synthesized)
5 Animal isolation of a substance (insulin) Simple peptides a.a sequencing machine Complex proteins recombinant DNA technology Receptology studies: Allowed synthesis of huge number of agonists and antagonists
6 However, as more would become known about detailed structure of receptors, rational drug design with aid of computers will become more feasible Rational drug design : This implies the ability to predict the chemical structure of drug molecule on basis of 3-dimensional structure of its receptor, employing at present suitable computer programs. Only few drugs in clinical use at present were developed in this rational way. Most drugs were in the past developed through random testing of chemicals, or modified molecules of known drugs that are known to have some other pharmacological effect.
7 Drug Nomenclature: - Chemical name e.g. acetyl salicylic acid - Generic name; nonproprietary; official; approved name... Aspirin (most widely used in pharmacology) - Official name... Aspirin BP; Aspirin USP - Trade name; Proprietary; brand name Remine ; Bufferin...etc
8 Preclinical testing In vitro studies Animal testing IND Clinical trials Long-term toxicity studies Phase 1 normal volunteers: safety, pharmacokinetics NDA Postmarketing surveillance (Phase 4) 1 to 5 years Phase 2 selected patients: therapeutic efficacy, dose range Phase 3 large populations of selected patients: therapeutic efficacy, safety in double blind studies 2 to 10 years Average years 1 year
9 3. Preclinical studies Studies on tissues and whole animals Determine efficacy Isolated tissue e.g. bronchi organ path testing drug etc Animal models drug BP drug blood sugar level
10 Determine pharmacokinetic parameters Absorption, distribution, metabolism etc Determine pharmacodynamics (MOA) Assessment of drug toxicity=safety Acute toxicity studies Determination of LD 50 ; Margin of safety etc Subacute and chronic toxicity studies. Repeated dose studies.
11 Daily observation of animals (wt., food and water intake..) Obtaining biological samples (blood; urine) Obtaining tissues (liver; spleen; stomach etc) for histopathological exam or studies
12 Special toxicology studies Mutagenicity (genotoxicity) tests Could delineate the induction of gene mutations (bacterial mutagenicity test or administration of drug to pregnant animals etc) Some mutations could result in the development of cancer
13 Carcinogenicity studies Not always required prior to early studies in man unless there is a high suspicion that the drug could be carcinogenic e.g. suspicion of mutagenicity; highly reactive groups on drug; histopathological abnormalities Required if the use of drug in man for more than one year or +ve mutagenic test
14 Phase 0 Phase 0 or first-in-human trials is a recent phase approved in accordance with the United States FDA s 2006 Guidelines Phase 0 trials are also known as human microdosing studies and are designed to speed up the development of promising drugs by establishing very early on whether the drug or agent behaves in human subjects as was expected from preclinical studies
15 Distinctive features of Phase 0 trials include the administration of single subtherapeutic doses of the study drug to a small number of subjects (10 to 15) to gather preliminary data on the agent's pharmacokinetics and pharmacodynamics. A Phase 0 study gives no data on safety or efficacy, being by definition a dose too low to cause any therapeutic effect. Drug development companies carry out Phase 0 studies to rank drug candidates in order to decide which has the best pharmacokinetic parameters in humans to take forward into further development.
16 Phase 0 studies enable go/no-go decisions to be based on relevant human models instead of relying on sometimes inconsistent animal data Questions have been raised by experts about whether Phase 0 trials are useful, ethically acceptable, feasible, speed up the drug development process or save money, and whether there is room for improvement.
17 Phase I Involves the use of a drug in humans for the first time It establishes dose level at which signs of toxicity first appear Conducted on healthy men with ages yrs
18 Usually a single dose is used initially and if no side effects exhibited, the dose is increased progressively until sufficient serum level is achieved (therapeutic level) or some toxic effects appear Such studies are conducted in hospital If no side effects result from single dose, multiple dose studies should be initiated =bioavailability-bioequivalence studies
19 Phase II If phase I studies prove that the drug is safe to continue, the new drug is administered to patients for the first time All patients should have only one problem (one disease) It assesses efficacy and establishes optimal dose range in patients (dose-response studies are important) Phase II studies are conducted on patients (certain countries ask for patients) Also patients are observed for toxicity to assess safety of the drug
20 Phase III Similar to phase II but conducted on large number of patients (several hundreds to thousands; reasonable) It also assesses safety and efficacy Could detect effects/side effects not observed in phase II
21 Phase IV Post-marketing studies Controlled and uncontrolled studies are often conducted after drug approval and marketing It further assesses safety & efficacy of drugs It allows for comparisons between different drugs used for the same disease
22 In addition, phase IV studies provide evidence of a new use to the drug e.g. aspirin-antiplatelet sildenafil citrate-ed Double-blind; single-blind placebo controlled studies are usually conducted
23 After all these clinical drug trials the drug is usually approved by national or International regulatory authorities and is licensed for General prescribing
24 Handout
25 Ethics of the use of drugs in humans Full detailed protocol has to be approved by the ethical committee, the institutional review board (IRB) All subjects should sign an informed agreement form All subjects should be insured for life and damage
26 Branches of pharmacology usually answer all of the following questions: - How much of a drug to give? Dose - How frequent a drug should be given? Related to the biological half-life (t 1/2 ) - When to give it? Before or after meals; at bed time, PRN... - How to give it? administration... etc
27 Factors affecting the dose Age Weight Route of administration Sex Factors affecting administration Physicochemical properties of drugs Site of action Status of patient Dosage interval
28 Schedule I Includes the drugs with high potential of Abuse Eg. LSD, Heroin.Marijuana, Flunitrazepam and Methaqualone Schedule II Includes morphine,codiene, pethidine, fentanyl, cocaine, amphetamine,methylphenidate, pentobarbital and secobarbital.these can be used under medical supervision only Schedule III Schedule IV Schedule V The drugs with moderate physical and psychological dependence eg. Stanzolol, ketamine,nalorphine,thiopental,suppository form of secobarbital and pentobarbital etc They have low potential for abuse and have limited physical and pshycological dependence eg. Long acting barbiturates,benzodiazapines, Propoxyphene,Pentazocine,Premolineolpidem and Zaleplon They have minimal use abuse potential and minimum dependence liability eg Lamotil and formulation containing Codiene while others are OTC drugs.,
29 DRUG PRESCRIBING AND DRUG COMPLIANCE
30 Therapeutic drug use could be for the following purposes: 1. Curative: seeking a cure for an existent disease or medical condition 2. Symptomatic: any medical therapy of a disease that only affects its symptoms, not its cause. 3. Replacement: Administration of a body substance to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the substance. 4. Supportive: is one that does not treat or improve the underlying condition, but instead increases the patient's comfort 5. Prophylactic or Preventive therapy: is a therapy that is intended to prevent a medical condition from occurring 6. Palliation: focuses on relieving and preventing the suffering of patients by addressing physical, emotional, spiritual and social concerns arising with illness. 30
31 Rational use of drugs: "patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to them and their community". Choice of effective drugs should be based on : 1.Efficacy 2. Cost: affordable by patient and community 3. Chosen from Essential Drugs: These are effective drugs that are commonly used in community, and must always be available 31
32 Rational drug prescribing is based on a series of steps: 1. Making a specific diagnosis 2. Consider the pathophysiologic implications of the diagnosis 3. Select the specific therapeutic objective 4. Select a drug of choice: Consider patient criteria (age, other drugs also taken, other diseases, and nature of disease) as well as his clinical presentation 5. Design the appropriate dosing regimen, based on patient pharmacokinetics and if they are altered by his illness 6. Monitor for therapeutic effect(s), patient compliance, and adverse effects 32
33 1. Untreated indication 2. Improper drug selection 3. Subtherapeutic dosage 4. Overdosage/toxicity 5. Failure to receive drug 6. Adverse drug reactions/events 7. Interactions 8. Drug use without indication 33
34 These are of two major types: 1. Hospital prescription of drugs: This is written by the treating doctor on the Physician Order Sheet (POS) of the patient hospital chart. It is preceded by the date which is put on upper left hand of chart. The prescription includes the drug(s) and direction of use i.e. for each drug : the dose to be given to patient and its route, frequency of administration, and duration of use. This followed by signature of the treating doctor. A typical chart order might be as follows: 14/10/ :00 a.m. (1) Ampicillin 500 mg IV q6h x 5 days (2) Aspirin 0.6 g per rectum q6h prn temp over 38c Signiture 34
35 2. Office prescription: This is the physician request to the pharmacist aimed at dispensing drug(s) in proper amount to patient together with directions for effective therapeutic use. The prescription includes the following parts: 1. Identification : Doctor : Name, speciality, address, telephone(optional) Patient : Name, age, address( optional) Date 2. Superscription : which includes the suffix Rx : Recipe (Receive Thou) 3. Inscription ( Body of prescription ): This includes the drug(s), dose form and its strength in metric units, and directions for proper use by patient 35
36 4. Subscription: This includes directions for dispensing the correct amount of drug for the patient according to frequency of use and duration of treatment. 5. Re-fill directions: if needed; any special warning to be given to patient regarding drug storage or use, and if there is a need for child-proof container for drug(s) 6. Signature of prescribing doctor & his license number: usually at bottom of prescription The pharmacist puts a label on each drug container and it includes the followings : Drug name and its nature Directions of its use and storage Warnings Expiry date of drug 36
37 Dr Name Academic and professional degree Address Telephone No. Patient name : Date:. Age (years): Address : Dignosis:. Rx : Panadol tb 500mg 1x3 x4 p.c Panadol tablets (0.5 g ) Take one tablet p.c. tid for 4 days Signature Re-fill : once Warning : non License No. Childproof container : none 37
38 Label on bottle : Panadol. Analgesic or antipyretic - take one tablet 3 times daily before meals for 4 days Expiry date : July 2016 Note : Trade or proprietory name is used in office prescriptions, while generic name is used in hospital prescriptions 38
39 Some abbreviations, in latin or Greek, that may be needed in writing directions of drug use in prescriptions : ac : ante cibum (before meals) pc : post cibum (after meals) bid : twice daily tid or tds : three times daily qid : four times daily prn : when needed qd : every day qh : every hour qhs : every night at bedtime ss : one half stat : at once OD : right eye OL : left eye OU : both eyes 39
40 Some Measurements that may be used in directions of drug use in prescriptions : one tea spoonfull = 5 ml one table spoonfull = 15 ml one ounce (oz.) = 30 ml one quart = 1000 ml one drop = 0.05 ml one ml = 20 drops Common errors in prescription writing are due to : 1. Omission of information 2. poor prescription writing 3. inappropriate choice of drug(s) 40
41 Drug Compliance : means the extent to which the patient follows the instructions of proper drug(s) use, as given by his prescribing doctor on the prescription form. Causes of poor compliance : 1. Lack of patient teaching by his Dr on details of proper drug use or lack of understanding by patient of these instructions when taught to him 2. Failure of patient to obtain the drug due to problems of cost or handicap 3. Patient forgets to take drug, or loss of drug, or discontinues taking drug prematurely and thus may donate the medication to others 41
42 4. Polypharmacy (taking multiple drugs) : due to many diseases esp. in elderly ; this is esp. when multiple doses of each drug is needed daily 5. Frequent doses (> 3 / d) and long duration of treatment (months or years) 6. Age : neonates, infants, children, and elderly 7. Disabling adverse effects occur Consequences of poor compliance : 1. Reduced or loss of therapeutic effect, esp. with drugs having short half-life 2. Recurrence of disease 3. Withdrawal syndrome occur with some drugs 42
43 Pharmacodynamics is the study of the biochemical and physiological effects of drugs, in certain period. In brief, it can be described as what the drug does to the body. Drug receptors Effects of drug Responses to drugs Toxicity and adverse effects of drugs
PHARMACY TECHNICIAN TRAINING COURSE Week #1
PHARMACY TECHNICIAN TRAINING COURSE Week #1 What we want to do this week: - Welcome! and complete some information on students - make sure we know how to use our calculators - learn about units and how
More informationUnit6. Prescriptions. Speaking:Giving A Prescription. Vocabulary: Common Latin Rx Terms. Articles: A Prescription: Understanding.
Unit6 Prescriptions Grammar: The Future: Will\ Going to Expressing the Future in Time Clauses Using the Present Progressive and Simple Present to Express Future Time Future Progressive Speaking:Giving
More informationNaloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program
Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program Andrea Leonard-Segal, M.D., M.S. Director, Division of Nonprescription Clinical Evaluation 1 Contents
More informationBasic Pharmacology. Drugs
Basic Pharmacology Drugs Basic Principles Study of drugs Actions Dosage Therapeutic uses (indications) Adverse effects Directly linked to the pathophysiology of a particular disease Drug = a substance
More informationIntroduction to Pharmacology
Introduction to Pharmacology 1 Definitions Drug: It is any chemical that affect living processes. It modifies an already existing function, and does not create a new function. 2 Pharmacology: Definitions
More informationMOD 4: Medication Administration
NSE22 Page 1 1. MOD 4: Medication Administration October1310 8:12 PM The CNO identifies eight rights of medication administration. Identify the eight rights and the rationale for each Right Client give
More informationHow Are Drugs Discovered?
DRUG EVALUATION & REGULATION M. Imad Damaj, Ph.D. Associate Professor Pharmacology and Toxicology Smith 656A, 828-1676, mdamaj@hsc.vcu.edu The Changed Context of Drug Discovery and Development The 1800s:
More informationBasic Principles in Pharmacology
L. 1 Dr. Mohammed AL-Zobaidy Basic Principles in Pharmacology Learning objectives: by the end of this lecture you should Understand the possible uses of drugs. Explain why a drug has different names. Identify
More informationINTRODUCTION. Dr Laith M Abbas Al-Huseini M.B.Ch.B, M.Sc., M.Res., Ph.D. epartment of Pharmacology and Therapeutics
INTRODUCTION Dr Laith M Abbas Al-Huseini M.B.Ch.B, M.Sc., M.Res., Ph.D. epartment of Pharmacology and Therapeutics Let s learn PHARMACOLOGY Greek Word Pharmacon Logos Drug Science Science of drugs- dealing
More informationWhich was the greatest problem with patent medicines in early America that lead to drug legislation?
Pharmacology Connections to Nursing Practice 3rd Edition Adams Test Bank Full Download: http://testbanklive.com/download/pharmacology-connections-to-nursing-practice-3rd-edition-adams-test-bank/ Adams
More informationChapter Goal. Learning Objectives 9/11/2012. Chapter 5. Emergency Pharmacology
Chapter 5 Emergency Pharmacology Chapter Goal Understand basic principles of pharmacology, & develop drug profiles for common emergency medications Learning Objectives Differentiate among chemical, generic
More informationBrand and Generic Drugs. Educational Objectives. Absorption
Peter J. Rice, PharmD, PhD Associate Professor of Pharmacology East Tennessee State University Educational Objectives Pharmacokinetic Processes Distribution Metabolism Excretion Similarities Active ingredient(s)
More informationLife Span Considerations
Life Span Considerations Learning Objectives 1. Discuss the influences of the patient s age on the effects of drugs and drug responses. 2. Identify drug-related concerns during pregnancy and lactation
More informationChloroform Codeine Ether
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Chapter 6, Part 1 GENERAL PRINCIPLES OF PHARMACOLOGY Part 1 Basic Pharmacology Drugs are chemicals used to diagnose, treat, and disease. Pharmacology is the study of drugs
More informationY. W. Francis Lam, Pharm.D. FCCP University of North Texas Health Science Center Grand Round Rx to OTC Switch: Potentials, Challenges, and Initiatives
1 Rx to OTC Switch Potentials, Challenges, and Initiatives Y. W. Francis Lam, Pharm.D., FCCP Professor of Pharmacology lamf@uthscsa.edu, 7-8355 Educational Goal Attendees will have an overall understanding
More informationPREREQUISITES: VETA 1104, VETA 1201 and MATH This class must be taken before or in conjunction with VETT 2100.
COURSE: VETT 2102 - Pharmacology for Veterinary Technicians CRN: CREDIT HOURS (Lecture/Lab/Total): 3/0/3 CONTACT HOUR (Lecture/Lab/Total): 45/0/45 INSTRUCTOR INFORMATION Name: Shawna Guidry Email: shawnaguidry@northshorecollege.edu
More information9. The phenomenon that occurs upon taking additional doses of acetaminophen for pain when a 100 percent response has been attained is called A.
1 Student: 1. The main source of new drugs derived today is: A. Synthetic sources B. Animal sources C. Plant sources D. Mineral sources 2. The nonproprietary name of a medication is also known as the:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Non-Benzodiazepine Insomnia Medications Reference Number: CP.CPA.265 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at
More informationReference ID: NDA was approved on December 12, The product was not formulated with properties to deter abuse,
tablets (NDA 020553). 1 According to Purdue, the reformulated OxyContin (OCR) had controlled-release features that would be less easily compromised by tampering than the original OxyContin (OC), and thereby
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Non-Benzodiazepine Insomnia Medications Reference Number: CP.HNMC.265 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder
More informationChapter 1: Fundamentals of Pharmacology Test Bank
Chapter 1: Fundamentals of Pharmacology Test Bank MULTIPLE CHOICE 1. By which of the following routes are drugs administered directly into the bloodstream? a. Enteral b. Transdermal c. Transmucosal d.
More informationTest Bank. 2. From the following list, select the items which are associated with drug names. a. brand b. generic c. trade d.
Instant download and all chapters Test Bank Oral Pharmacology for the Dental Hygienist 2nd Edition Mea A. Weinberg, Cheryl Westphal Theile, James Burke Fine https://testbankdata.com/download/test-bank-oral-pharmacology-dentalhygienist-2nd-edition-mea-weinberg-cheryl-westphal-theile-james-burke-fine/
More informationFDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES
FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES 1 SCOPE In pursuance of section 47 of the Food and Drugs Law 1992, P.N.D.C.L 305B, as amended by Act 523, 1996, these
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.CPA.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder
More informationSLCC Math 1020 Fall 2010 Final Exam Name: Part I: You are not allowed to use calculators, books, or notes. Answer all questions. Do it by yourself.
SLCC Math 1020 Fall 2010 Final Exam Name: Part I: You are not allowed to use calculators, books, or notes. Answer all questions. Do it by yourself. 1. Use the adult s nomogram to find the BSA of a person
More informationRequirements to the Registration of Medicinal products in the Republic of Armenia
Requirements to the Registration of Medicinal products in the Republic of Armenia Yerevan 2010 Requirements to the Registration of Medicinal products in the Republic of Armenia Current requirements to
More informationMedication Safety Presentation
Appendix E Aid 1: Sample Event Poster Medication Safety Presentation Do YOU know your role on the healthcare team? Do YOU know the questions to ask your pharmacist? Do YOU know safe medication practices?
More informationCHAPTER 1 COMMUNITY PHARMACY M.ASHOKKUMAR DEPT OF PHARMACY PRACTICE SRM COLLEGE OF PHARMACY SRM UNIVERSITY
CHAPTER 1 COMMUNITY PHARMACY M.ASHOKKUMAR DEPT OF PHARMACY PRACTICE SRM COLLEGE OF PHARMACY SRM UNIVERSITY COMMUNITY PHARMACY OPERATIONS Technician Duties Related to Dispensing Over-the-Counter Drugs and
More informationDo not open the test booklet prior to being told to do so.
Last Name: Pharmacy 4054 Pharmacy Law Exam II Do not open the test booklet prior to being told to do so. I, the undersigned student, agree to do my best on the exam and that I have only used resources
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.HNMC.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationPain Module. Top Ten Pain Safety Tips
Pain Module Top Ten Pain Safety Tips # 1 Monitor Your Patient s Level of Consciousness and Respiratory Status Do not depend on alarms to save your patient s life. You must perform your own assessments
More informationADVERSE REACTIONS The most common (>10%) adverse reactions are hypercalcemia, nausea, and diarrhea. (6.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PHOSLYRA safely and effectively. See full prescribing information for PHOSLYRA. PHOSLYRA (calcium
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationOklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationDrug CHAPTER 2. Pharmacologic Principles. NDEG 26A Eliza Rivera-Mitu, RN, MSN. Pharmacology. Drug Names. Pharmacologic Principles. Drug Names (cont'd)
CHAPTER 2 Pharmacologic Principles NDEG 26A Eliza Rivera-Mitu, RN, MSN Drug Any chemical that affects the physiologic processes of a living organism Pharmacology The study or science of drugs Drug Names
More information1. A patient receives the wrong drug (ex. verified Amox 875 drug dispensed should have been Augmentin 875)
July 12, 2018 Topic: Errors and Omissions Medications errors are made everyday. It is the job of the Pharmacist to prevent these errors from occurring. The right drug to the right patient at the right
More informationMarket Share & Competition
Psych 181: Lecture 3 Overview of Pharmaceutical Industry Drug nomenclature and classification Pharmacokinetics Pharmacodynamics Professor Anagnostaras Market Share & Competition Pharmaceutical Automobile
More informationVirginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationCOPYRIGHTED MATERIAL. Introduction
1 Introduction Pharmacology is the science of drugs and their effects on biological systems. A drug can be defined as a chemical that can cause a change in a biological system; the important biological
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationDo Not Reproduce. Things to Tell Your Health Care Provider
Note: This CareKit does not replace expert medical care. 2 Things to Tell Your Health Care Provider Before medicine is prescribed, tell him or her: Medicines on your health plan s preferred drug list (formulary).
More information6) One tablespoon is equivalent to how many milliliters?
Name Date 1) The patient has dropped off the prescription. In the diagram below what does the letter X represent in relation to workflow terminology? Drop Offà X à Fillà Verificationà Y a) Pickup b) Order
More informationClinical Pharmacology and Prescribing
1 Clinical Pharmacology and Prescribing Dr Susannah O Sullivan Department of Pharmacology 2 Objectives Recognise the importance of clinical pharmacology as the scientific discipline that underpins a rational
More informationMAINTAINING COMPLIANCE IN GLAUCOMA PATIENTS. by : Abdalla El-Sawy, M.D. Professor of Ophthalmology, Benha Faculty of Medicine.
MAINTAINING COMPLIANCE IN GLAUCOMA PATIENTS by : Abdalla El-Sawy, M.D. Professor of Ophthalmology, Benha Faculty of Medicine. The problem is especially critical for eye doctors who manage patients with
More informationMath Department. Shane Tang Medical Math vs Intermediate Algebra. Section Identification Code: S061
Shane Tang Shane.Tang@slcc.edu Medical Math vs Intermediate Algebra AMATYC Section Identification Code: S061 October 31, 2013 The scariest day of the year! Abstract Pre-nursing students can improve their
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationChapter 5. The Actions of Drugs. Origins of Drugs. Names of Drugs. Most drugs come from plants or are chemically derived from plants
Chapter 5 The Actions of Drugs Origins of Drugs Most drugs come from plants or are chemically derived from plants Names of Drugs Chemical name: Complete chemical description of the molecule Example: N'-[2-[[5-(dimethylaminomethyl)-2-furyl]
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMEDICATION PORTFOLIO Medication Generic Brand Pharmkinetics. Other nursing implications. Dose / route. Pharmdynamics. Side effects
MEDICATION PORTFOLIO Medication Generic Brand Pharmkinetics Pharmdynamics Dose / route Side effects Other nursing implications History of Pharmacology Pharmacology- the study of what happens to the human
More informationNucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta
More informationMedication Information for Parents and Teachers
Medication Information for Parents and Teachers General Information About Medication Melatonin Each child and adolescent is different. No one has exactly the same combination of medical and psychological
More informationSUBSYS National Drug Code Directory
20482-016-15 SUBSYS The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated,
More informationEducation Program for Prescribers and Pharmacists
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)
More informationMedication Abbreviations
ABBREVIATIONS: QUIZ 2 Medication Abbreviations 1. Which one of the following abbreviations means antidiuretic hormone? a. AH b. AD c. AIDS d. AS e. ADH 2. Which of the following abbreviations means in
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationClinical Policy: Budesonide (Uceris) Reference Number: CP.PCH.11 Effective Date: Last Review Date: Line of Business: Commercial, HIM*
Clinical Policy: (Uceris) Reference Number: CP.PCH.11 Effective Date: 08.14.18 Last Review Date: 11.18 Line of Business: Commercial, HIM* Revision Log See Important Reminder at the end of this policy for
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationHow to Manage Medications Caregiving Series
How to Manage Medications Caregiving Series Objectives Upon completion of this training, the participant will: Learn the warning signs of improper medication use Have an understanding of how aging changes
More informationKANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998
KANSAS Kansas State Board of Healing Arts Source: Kansas State Board of Healing Arts Approved: October 17, 1998 GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF PAIN Section 1: Preamble
More informationWorld Health Organization (2000)
World Health Organization (2000) This document is not a formal publication of the World Health Organization (WHO). All rights are reserved by WHO. The document may, however, by freely reviewed, abstracted,
More informationRevised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017
Revised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017 A. Application of Guidelines Guidelines on Proper Prescription
More informationAbout the PCTB Examination Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p.
Preface p. ix About the PCTB Examination p. xii Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p. 4 The Retail Medication Order p. 6
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationPATIENT CASE HISTORY. General Health Medications Allergies
OCULAR PHARMACOLOGY What I Need to Know Before I Medicate A Patient Lynn Lawrence, CPOT, ABOC, COA ROLE of the ASSISTANT AND TECHNICIAN Accurate documentation/recording Patient Education can assist in
More informationCandidate Information Sheet Therapeutic Decision Making Examination For Practice Ready Assessment (PRA) Selection Process
Candidate Information Sheet Therapeutic Decision Making Examination For Practice Ready Assessment (PRA) Selection Process For the purposes of the Therapeutics Decision-making (TDM) examination, therapeutics
More informationClinical Policy: Cinacalcet (Sensipar) Reference Number: CP.PHAR.61 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Sensipar) Reference Number: CP.PHAR.61 Effective Date: 05.01.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationFundamentals of Pharmacology for Veterinary Technicians Chapter 1
1906 1914 1933 1937 1938 1941 1951 1965 1968 1970 1970 1972 1972 1983 1984 1988 1994 1994 1996 1997 2001 2003 2008 The original Pure Food and Drug Act is passed by Congress on June 30 and signed by President
More informationNEW ZEALAND DATASHEET
NEW ZEALAND DATASHEET COLDREX HOT REMEDY COLD & FLU HOT LEMON Powder for Oral Solution Paracetamol (BP) 1000mg/sachet Presentation Pale yellow, free flowing heterogeneous powder with and odour of lemon
More informationAN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE
AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE Valerie Carrejo, MD Assistant Professor UNM Family Medicine Advances in Primary Care April 14, 2017 Objectives Review the basic
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Non-Benzodiazepine Insomnia Reference Number: CP.PMA_10.11.23 Effective Date: 07.16 Last Review Date: 04.18 Line of Business: Medicaid- Arizona (AHCS, CIC) Revision Log See Important Reminder
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationMissouri Guidelines for the Use of Controlled Substances for the Treatment of Pain
Substances for the Treatment of Pain Effective January 2007, the Board of Healing Arts appointed a Task Force to review the current statutes, rules and guidelines regarding the treatment of pain. This
More informationInterchangeable Drug Products - Additional Criteria
Interchangeable Drug Products - Additional Criteria Principle: Decisions respecting interchangeability and drug lists remain in the domain of the institution responsible for the costs of the product which
More informationDISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.
DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: April 21, 2017 Purpose The intent of this document is to provide
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationCase Study Activity: Strategies to Support the Safe Use of Acetaminophen
Case Study Activity: Strategies to Support the Safe Use of Acetaminophen Case 3: Preventing Therapeutic Duplication With Over-the-Counter Acetaminophen Products Activity Preview Acetaminophen is one of
More informationOpioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective
Opioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective February 13, 2018 Frank Vocci, PhD New Therapies on the Horizon The planners, editors, faculty and reviewers of this activity
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Relistor) Reference Number: CP.CPA.274 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationInjury Severity Score
Injury Severity Score Body system Injury severity Points Head and neck No injury 0 Face Minor 1 Chest Moderate 2 Abdomen Serious 3 Extremity, inc pelvis Severe 4 External Critical 5 Unsurvivable 6 http://www.trauma.org/archive/scores/iss.html
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationClinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics Updated on 23 Feb 2017 I) OBJECTIVES 1. To provide a broad training and in-depth experience at a level sufficient for trainees to acquire competence and professionalism
More informationPharmacology for Pharmacy Technicians. Pharmacology. Pharmacology, cont'd. Fundamentals of Pharmacology
Pharmacology for Pharmacy Technicians Fundamentals of Pharmacology Pharmacology Pharmacy technicians have the skills to refill a prescription based on the patient s profile. Pharmacy technicians have good
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationDOSAGE FORMS AND STRENGTHS Cream: Each gram contains 10 mg of ozenoxacin (1%) (3).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XEPI TM safely and effectively. See full prescribing information for XEPI TM. XEPI TM (ozenoxacin)
More informationLUNG CANCER CLINICAL TRIALS
UNDERSTANDING SERIES LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT THE BASICS ABOUT CLINICAL TRIALS WITH MORE INFORMATION YOU CAN MAKE BETTER CHOICES. The decision
More informationDRUG DEVELOPMENT. How do drugs become available for prescription?
DRUG DEVELOPMENT How do drugs become available for prescription? OUTLINE Birth Idea, Chemistry, Pharmacology. Obtaining a patent. Passing regulatory hurdles (IND and NOC) Pre-clinical trials and data.
More informationEverything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY
Everything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY Objectives AT THE COMPLETION OF THIS ACTIVITY, THE PHARMACIST PARTICIPANT WILL BE ABLE TO:
More informationVermont. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of
More informationEverything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY
Everything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY Objectives AT THE COMPLETION OF THIS ACTIVITY, THE PHARMACIST PARTICIPANT WILL BE ABLE TO:
More informationAfter i.v injection 45% of the amount of desmopressin is found in the urine within 24 hours.
MINIRIN Tablets 0.1 and 0.2 mg Declaration Tablets 0.1 mg. Each tablet contains desmopressin acetate 0.1 mg and excipients q.s Tablets 0.2 mg. Each tablet contains desmopressin acetate 0.2 mg and excipients
More informationTest Bank for Basic Pharmacology for Nurses 14th edition by Clayton, Stock and Harroun
Test Bank for Basic Pharmacology for Nurses 14th edition by Clayton, Stock and Harroun Link download full: https://digitalcontentmarket.org/download/testbank-for-basic-pharmacology-for-nurses-14thedition-by-clayton-stock-harroun
More informationClinical Study Reports (Uncontrolled studies)
Clinical Study Reports (Uncontrolled studies) Clinical Study Report Study 1 Study Title Clinical Evaluation of Efficacy and Safety of Kilose Capsule on Obesity: An Open Clinical Trial Test Facility M.S.
More information